Preface -- 1 Introduction -- 2 The continuously expanding universe of Entamoeba -- 3 The genomics of Entamoebae: insights and challenges -- 4 Multilocus sequence typing system (MLST): Genetic diversity and genetic components to virulence -- 5 The tRNA gene-linked STRs and other genetic typing methods -- 6 Genetic manipulation techniques -- 7 Surveying Entamoeba histolytica transcriptome using massively parallel cDNA sequencing -- 8 Ribosomal RNA Genes and their Regulation in Entamoeba histolytica -- 9 Small RNAs and regulation of gene expression in Entamoeba histolytica -- 10 The Biology of Retrotransposition in Entamoeba histolytica -- 11 Entamoeba histolytica: Bridging the gap between environmental stress and epigenetic regulation -- 12 Phagocytosis in Entamoeba histolytica -- 13 Signalling pathways in E. histolytica -- 14 Transmembrane Kinases and their role in E. histolytica pathogenesis -- 15 Cell surface molecules as virulence determinants in Entamoeba histolytica -- 16 Mechanism of cell division in Entamoeba histolytica -- 17 Molecular basis of the trafficking of cysteine proteases and other soluble lysosomal proteins in Entamoeba histolytica -- 18 Mitosomes in Entamoeba histolytica -- 19 Metabolomic analysis of Entamoeba biology -- 20 Glucose metabolism and its controlling mechanisms in Entamoeba histolytica -- 21 Structural Biology of Cysteine Biosynthetic Pathway Enzymes -- 22 Archetypical and specialized DNA replication proteins in Entamoeba histolytica -- 23 Pathology, pathogenesis and experimental amebiasis -- 24 Innate Host Defenses in the Gut -- 25 Cysteine peptidases in pathogenesis -- 26 Host immunity and tissue destruction during liver abscess formation -- 27 The Effect of E. histolytica on Muc2 Mucin and Intestinal Permeability -- 28 Human Genetic Susceptibility to Amebiasis -- 29 Immune Response in Human Amoebiasis: a protective response? -- 30 Metronidazole and the Redox Biochemistry of Entamoeba histolytica -- 31 Thioredoxin Reductase and its Role as a New Drug Target -- 32 Drug development: old drugs and new lead -- 33 HETEROCYCLIC LEAD COMPOUNDS AGAINST AMOEBIASIS.